Key Highlights
- Michael Byrnes named Chief Financial Officer at FORE Biotherapeutics.
- Over 20 years of experience in biotech industry, leading multiple companies through equity, debt, and M&A transactions.
- Former CFO of eFFECTOR Therapeutics; instrumental in taking the company public in 2021.
- FORE Biotherapeutics continues to strengthen its leadership team, including recent hire Payman Darouian.
Source: Business Wire
Notable Quotes
- “I am excited to have Mike join as our CFO. He brings highly relevant experience to Fore given his background and track record in both private and public companies. He will be a key leader in supporting the performance and growth of the company.” — Bill Hinshaw, CEO at Fore Biotherapeutics
- “I’m excited to join Fore as chief financial officer and leverage my extensive experience from multiple high-growth biotechnology companies. This is an exciting time to join Fore, with multiple value-creating catalysts anticipated in the near-term and going forward across the trials.” — Michael Byrnes, CFO at Fore Biotherapeutics
SoHC's Take
The appointment of Michael Byrnes as CFO marks a strategic move for FORE Biotherapeutics, as his extensive background in finance and biotechnology positions him to effectively guide the company through its next phase of growth. Byrnes’ experience in taking companies public and overseeing significant M&A transactions aligns well with FORE’s ambitious goals, particularly as the company continues to advance its lead asset, plixorafenib. His addition to the leadership team is a clear signal of FORE’s commitment to fortifying its executive expertise as it navigates the complexities of oncology drug development and commercialization.
